| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
NMIA does not have a biological target in the context of pharmacology. It is a chemical reagent used for RNA structure analysis in biochemical research. NMIA selectively acylates the 2'-hydroxyl group of ribose in RNA, which is more reactive when the RNA is in a flexible, single-stranded conformation. The acylation reaction modifies the RNA, and the sites of modification are detected by primer extension analysis, providing information about RNA secondary structure.
|
|---|---|
| ln Vitro |
In vitro, NMIA is used to modify RNA molecules by selectively acylating the 2'-hydroxyl group of ribose. The acylation reaction is dependent on the conformation of the RNA, with flexible regions being more reactive. The modified RNA is then analyzed by primer extension to identify the sites of modification, which correlate with single-stranded regions of the RNA. NMIA is widely used in SHAPE analysis to determine RNA secondary structure.
|
| ln Vivo |
NMIA is not a pharmacologically active compound and is not evaluated for in vivo activity. Its applications are limited to in vitro RNA structure analysis in biochemical research. No in vivo efficacy studies are conducted for NMIA because it is not intended to treat any disease.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to NMIA because it is a chemical reagent rather than a drug candidate. However, the compound may be characterized by physicochemical methods such as HPLC for purity analysis, melting point determination, and solubility testing. Its reactivity with RNA 2'-hydroxyl groups can be assessed using model RNA substrates to confirm its functionality as a SHAPE reagent.
|
| Cell Assay |
In vitro cellular assays are not typically performed for NMIA because it is a reagent rather than a drug candidate. When used in cell culture, NMIA may be applied to cells to modify cellular RNA for structure analysis. However, these applications are for research purposes rather than therapeutic evaluation.
|
| Animal Protocol |
NMIA is not a pharmacologically active compound and is not evaluated for in vivo therapeutic efficacy. No in vivo animal experiments are conducted for NMIA because it is not intended for therapeutic use. The compound is used exclusively in biochemical research for RNA structure analysis.
|
| ADME/Pharmacokinetics |
NMIA has a molecular weight of 177.16 g/mol and a molecular formula of C9H7NO3. It is a white to yellow solid powder with a melting point of 175.0-180.0°C. The compound is soluble in DMSO at 10 mM and should be stored at room temperature under an inert gas to avoid moisture. It has a relative density of 1.3312 g/cm3.
|
| Toxicity/Toxicokinetics |
The toxicological profile of NMIA has not been extensively characterized because it is a research reagent rather than a drug candidate. Standard safety precautions should be followed when handling the compound, including the use of appropriate personal protective equipment. No significant toxicity has been reported. Comprehensive toxicology studies are not necessary for this reagent, as it is not intended for human use.
|
| Additional Infomation |
N-Methylisoindocyanine anhydride is a 3,1-benzoxazine-1,4-dione with an N-methyl substituent.
NMIA is a chemical reagent used for RNA structure analysis in biochemical research. It is also known as N-Methylisatoic anhydride. NMIA is a 2'-OH selective acylation agent of RNAs and is widely used for resolving secondary RNA structures using the SHAPE technology. NMIA is a research reagent and is not intended for therapeutic use. |
| Molecular Formula |
C9H7NO3
|
|---|---|
| Molecular Weight |
177.159
|
| Exact Mass |
177.043
|
| CAS # |
10328-92-4
|
| PubChem CID |
25160
|
| Appearance |
White to yellow solid powder
|
| Density |
1.348 g/cm3
|
| Boiling Point |
297.5ºC at 760 mmHg
|
| Melting Point |
165 °C (dec.)(lit.)
|
| Flash Point |
133.7ºC
|
| Vapour Pressure |
0.00135mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
0.491
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
13
|
| Complexity |
251
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N(C)C1=CC=CC=C12)OC2=O
|
| InChi Key |
KJMRWDHBVCNLTQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H7NO3/c1-10-7-5-3-2-4-6(7)8(11)13-9(10)12/h2-5H,1H3
|
| Chemical Name |
1-methyl-3,1-benzoxazine-2,4-dione
|
| Synonyms |
N-Methylisatoic Anhydride; NMIA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~564.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6446 mL | 28.2231 mL | 56.4462 mL | |
| 5 mM | 1.1289 mL | 5.6446 mL | 11.2892 mL | |
| 10 mM | 0.5645 mL | 2.8223 mL | 5.6446 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
